FR13C0032I2 - Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif - Google Patents

Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif

Info

Publication number
FR13C0032I2
FR13C0032I2 FR13C0032C FR13C0032C FR13C0032I2 FR 13C0032 I2 FR13C0032 I2 FR 13C0032I2 FR 13C0032 C FR13C0032 C FR 13C0032C FR 13C0032 C FR13C0032 C FR 13C0032C FR 13C0032 I2 FR13C0032 I2 FR 13C0032I2
Authority
FR
France
Prior art keywords
remedy
acetic acid
active ingredient
overactive bladder
anilide derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0032C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0032(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of FR13C0032I1 publication Critical patent/FR13C0032I1/fr
Application granted granted Critical
Publication of FR13C0032I2 publication Critical patent/FR13C0032I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR13C0032C 2002-11-07 2013-06-19 Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif Active FR13C0032I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07
PCT/JP2003/014065 WO2004041276A1 (ja) 2002-11-07 2003-11-04 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤

Publications (2)

Publication Number Publication Date
FR13C0032I1 FR13C0032I1 (OSRAM) 2013-08-09
FR13C0032I2 true FR13C0032I2 (fr) 2014-03-07

Family

ID=32310425

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0032C Active FR13C0032I2 (fr) 2002-11-07 2013-06-19 Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif

Country Status (28)

Country Link
US (5) US20060115540A1 (OSRAM)
EP (1) EP1559427B1 (OSRAM)
JP (1) JP3815496B2 (OSRAM)
KR (1) KR100967070B1 (OSRAM)
CN (1) CN100406011C (OSRAM)
AT (1) ATE500827T1 (OSRAM)
AU (1) AU2003284700B2 (OSRAM)
BE (1) BE2013C040I2 (OSRAM)
BR (1) BR0316080A (OSRAM)
CA (1) CA2503570C (OSRAM)
CY (2) CY1111399T1 (OSRAM)
DE (1) DE60336334D1 (OSRAM)
DK (1) DK1559427T3 (OSRAM)
ES (1) ES2360353T3 (OSRAM)
FR (1) FR13C0032I2 (OSRAM)
HU (1) HUS1300027I1 (OSRAM)
IL (1) IL168121A (OSRAM)
LU (1) LU92218I2 (OSRAM)
MX (1) MXPA05004925A (OSRAM)
NL (1) NL300599I2 (OSRAM)
NO (2) NO334948B1 (OSRAM)
NZ (1) NZ539577A (OSRAM)
PL (1) PL211687B1 (OSRAM)
PT (1) PT1559427E (OSRAM)
RU (1) RU2321401C2 (OSRAM)
SI (1) SI1559427T1 (OSRAM)
WO (1) WO2004041276A1 (OSRAM)
ZA (1) ZA200503510B (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
PL2216021T3 (pl) 2007-11-02 2013-03-29 Astellas Pharma Inc Kompozycja farmaceutyczna do leczenia zespołu pęcherza nadreaktywnego
CA2709727A1 (en) 2007-12-21 2009-07-02 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010053068A1 (ja) * 2008-11-07 2010-05-14 大日本住友製薬株式会社 新規で有用な下部尿路症状治療剤
WO2010147830A2 (en) * 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
JP5849947B2 (ja) * 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
WO2011122523A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
WO2012156998A2 (en) * 2011-05-18 2012-11-22 Dr. Reddy's Laboratories Limited Amorphous mirabegron and processes for crystal forms of mirabegron
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
EP2832730A4 (en) 2012-03-30 2015-09-09 Astellas Pharma Inc MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
CN104602693A (zh) 2012-08-31 2015-05-06 安斯泰来制药株式会社 口服给药用药物组合物
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103193658A (zh) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
MX2016001030A (es) * 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
EP3220942B1 (en) 2014-11-20 2022-04-27 Serenity Pharmaceuticals LLC Compositions comprising low dose desmopressin in combination with an alpha-adrenergic receptor antagonist
CN104496841B (zh) * 2014-11-26 2017-01-25 南京工业大学 一种米拉贝隆中间体的合成方法
CN104744292A (zh) * 2015-03-11 2015-07-01 南京工业大学 (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 一种米拉贝隆中间体的后处理方法
PT3360866T (pt) 2017-02-14 2019-02-19 Tiefenbacher Alfred E Gmbh & Co Kg Pró-fármacos de mirabegrom
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
JP7113434B2 (ja) 2017-05-31 2022-08-05 Ｓｂｉファーマ株式会社 過活動膀胱の予防剤または治療剤
CN117695286A (zh) 2017-06-06 2024-03-15 住友制药(苏州)有限公司 使用维贝隆以治疗膀胱过度活动症
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
WO2019013583A2 (ko) 2017-07-14 2019-01-17 주식회사 대웅제약 약제학적 제제 및 그 제조방법
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
EP4545072A3 (en) 2018-12-05 2025-07-02 Urovant Sciences GmbH Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
EP4410279A1 (en) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. A film tablet comprising mirabegron
KR20240171516A (ko) 2023-05-30 2024-12-09 주식회사 디앤아이바이오 미라베그론 서방정
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (ja) 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
JPH08509491A (ja) 1993-04-26 1996-10-08 藤沢薬品工業株式会社 胃腸疾患の治療に有用なエタノールアミン誘導体
JPH07228543A (ja) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
DE69628051T2 (de) 1995-10-26 2004-02-26 Mitsubishi Pharma Corp. Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
WO1998000016A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
CA2263659A1 (en) 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
JP2001513551A (ja) * 1997-08-28 2001-09-04 アフェロン コーポレイション 尿失禁の治療
TW557295B (en) * 1997-10-17 2003-10-11 Yamanouchi Pharma Co Ltd Amide derivatives or salts thereof
CA2315235C (en) 1997-12-18 2009-07-28 Kissei Pharmaceutical Co., Ltd. Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
US6696489B1 (en) 1998-04-14 2004-02-24 Kissei Pharmaceutical Co., Ltd. 2-Methylpropionic acid derivatives and medicinal compositions containing the same
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
CA2362586A1 (en) * 1999-02-12 2000-08-17 Genset S.A. Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) * 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
AUPQ585000A0 (en) * 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (es) * 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
CA2646729A1 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence

Also Published As

Publication number Publication date
NZ539577A (en) 2007-06-29
MXPA05004925A (es) 2005-08-18
KR20050072809A (ko) 2005-07-12
NO20052691L (no) 2005-07-15
CY2013023I1 (el) 2015-10-07
CY1111399T1 (el) 2015-08-05
JP3815496B2 (ja) 2006-08-30
NO2015001I2 (no) 2015-01-26
CY2013023I2 (el) 2015-10-07
PL376771A1 (pl) 2006-01-09
ES2360353T3 (es) 2011-06-03
US20110230530A1 (en) 2011-09-22
US8835474B2 (en) 2014-09-16
BE2013C040I2 (OSRAM) 2023-03-07
NO334948B1 (no) 2014-08-04
BR0316080A (pt) 2005-09-27
AU2003284700B2 (en) 2009-05-28
LU92218I2 (fr) 2014-01-07
SI1559427T1 (sl) 2011-06-30
RU2005117367A (ru) 2006-01-20
CA2503570A1 (en) 2004-05-21
AU2003284700A1 (en) 2004-06-07
CN1711085A (zh) 2005-12-21
ATE500827T1 (de) 2011-03-15
EP1559427B1 (en) 2011-03-09
JPWO2004041276A1 (ja) 2006-03-02
US20090093529A1 (en) 2009-04-09
PL211687B1 (pl) 2012-06-29
RU2321401C2 (ru) 2008-04-10
NL300599I2 (OSRAM) 2017-01-03
IL168121A (en) 2011-12-29
HUS1300027I1 (hu) 2016-08-29
DE60336334D1 (de) 2011-04-21
ZA200503510B (en) 2006-12-27
USRE44872E1 (en) 2014-04-29
CN100406011C (zh) 2008-07-30
NO2015001I1 (no) 2015-01-19
EP1559427A1 (en) 2005-08-03
NO20052691D0 (no) 2005-06-06
US20060115540A1 (en) 2006-06-01
KR100967070B1 (ko) 2010-07-01
EP1559427A4 (en) 2007-05-30
WO2004041276A1 (ja) 2004-05-21
LU92218I9 (OSRAM) 2019-01-17
US7750029B2 (en) 2010-07-06
DK1559427T3 (da) 2011-04-26
FR13C0032I1 (OSRAM) 2013-08-09
PT1559427E (pt) 2011-05-27
CA2503570C (en) 2011-04-19

Similar Documents

Publication Publication Date Title
FR13C0032I2 (fr) Remede pour vessie hyperactive comprenant un derive anilide de l'acide acetique en tant qu'ingredient actif
EP3192506C0 (en) AGENTS FOR THE PROPHYLAXIS/RELIEF OF ADULT DISEASES CONTAINING 5-AMINOLEVULINIC ACID, A 5-AMINOLEVULINIC ACID DERIVATIVE OR A 5-AMINOLEVULINIC ACID SALT OR 5-AMINOLEVULINIC ACID DERIVATIVE AS ACTIVE INGREDIENT
EP1773768A4 (en) Pyrrolid derivatives as pharmaceutical active substances
NO20071042L (no) 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
HUS1600061I1 (hu) 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-2-pirimidinil]amino]benzonitril
EP1758854A4 (en) PYRROLIDIN-3-YL COMPOUNDS SUITABLE AS BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP2196206A4 (en) MEDICAMENT FOR TREATING SKIN PROBLEMS WITH A MORPHINE DERIVATIVE OR PHARMACOLOGICALLY COMPATIBLE ACIDIC ACID SALT AS AN ACTIVE SUBSTANCE
DE60025961D1 (de) Verwendung von Estern von L-Carnitinsäure oder von Alkanoyl L-Carnitinsäure als kationische Lipide für die intrazelluläre Verabreichung therapeutischer Stoffe
EP2214680A4 (en) PHARMACEUTICAL FORMULATION OF CLAVLANIC ACID
WO2009145816A3 (en) Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
WO2007134038A3 (en) Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
EP1073662A4 (en) METHOD FOR PRODUCING (-) PYRIDOBENZOXAZINE-CARBONIC ACID DERIVATIVES
CO6270204A2 (es) Soluciones farmaceuticas orales que contienen telbivudina
IS6284A (is) Meðhöndlun á mígreni með því að gefa alfa-lípósýru eða afleiður hennar
EP1650212A4 (en) OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT, METHOD FOR THE PRODUCTION THEREOF, AND METHOD FOR THE PRODUCTION OF AN OPTICALLY ACTIVE ALPHA-AMINO-ACID DERIVATIVE THEREWITH
BR0214780A (pt) Sal de ácido cìtrico de um composto terapêutico e composições farmacêuticas deste
EP1776100A4 (en) CANCER TREATMENT WITH BENZOIC ACID DERIVATIVES
MA29560B1 (fr) Formulation a liberation prolongee de principes actifs de medicaments
FR2883472B1 (fr) Utilisation d'un acide chlorogenique en tant qu'un actif amincissant
EP2340841A4 (en) OSTEOGENESEPROMOTER WITH [4- (METHYLTHIO) PHENYLTHIO] METHACISPHOSPHONIC ACID OR PHARMACEUTICAL ACCEPTABLE SALT AS AN ACTIVE SUBSTANCE
WO2004039377A8 (en) Use of piperazine sulfonic acid derivatives as ccr1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders
IL169496A0 (en) Imino acid derivatives for use as inhibitors of matrix metalloproteinases
NO20032035D0 (no) Terapeutiske midler for heratokonjunktivitis sykdommer omfattende farnesyleddiksyre som aktiv ingrediens
IS8225A (is) 2-etoxý-3-fenýlprópíónsýruafleiður til að meðhöndla fitusjúkdóma
ITTO20020102A1 (it) Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili.